Welcome to our dedicated page for GNHAY news (Ticker: GNHAY), a resource for investors and traders seeking the latest updates and insights on GNHAY stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GNHAY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GNHAY's position in the market.
CSL Limited (ASX: CSL; USOTC: CSLLY) announced an update on its acquisition of Vifor Pharma AG, originally expected to close by June 2022. While some antitrust approvals have been received, others are still pending. CSL reassured shareholders that such delays are common and that they are collaborating with remaining authorities for timely resolution. A precise closing date will be communicated once all regulatory approvals are confirmed, and CSL remains confident in finalizing the acquisition.
Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma announced that the European Commission has granted marketing authorization for Kapruvia® (difelikefalin). This is the first approved therapy for chronic kidney disease-associated pruritus in hemodialysis patients across Europe. Following FDA approval in August 2021, Kapruvia® is set to launch in the second half of 2022. Clinical data from phase-III trials demonstrated significant reductions in pruritus severity and improved quality of life for patients. The drug addresses a substantial unmet need in CKD management.
At the 94th Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions by the Board of Directors, including the Annual Financial Statements and the Remuneration Report. A dividend of CHF 2.00 was approved, payable from May 3, 2022. The meeting re-elected all current Board members, including Chairman Jacques Theurillat, and conditionally elected new members to the Board, effective upon settlement of CSL Behring AG's tender offer on January 18, 2022.
Vifor Pharma announced full results from the phase-IIIb DIAMOND trial for Veltassa® (patiromer), demonstrating its efficacy in controlling potassium levels in heart failure patients on RAASi therapy. The trial, with over 1,000 participants, showed a 37% reduction in hyperkalemia events and enabled more patients to maintain optimal RAASi dosing. The findings were presented at the ACC's 71st Annual Scientific Session. Veltassa® was well tolerated, highlighting its potential to improve patient outcomes by minimizing the risk of potassium buildup.
CSL Behring AG, a subsidiary of CSL Limited (ASX: CSL; USOTC: CSLLY), announced the end result of its public tender offer to acquire Vifor Pharma Ltd. for USD 179.25 per share. As of March 22, 2022, CSL's stake in Vifor Pharma reached 93.9%, subject to certain conditions. CSL intends to facilitate Vifor Pharma's de-listing and a squeeze-out of remaining shareholders. The offer's settlement is expected around mid-2022, pending regulatory approvals. Further details can be found at csltransaction.com.
CSL Behring AG, a subsidiary of CSL Limited (ASX: CSL; USOTC: CSLLY), announced a provisional result regarding its public tender offer for Vifor Pharma Ltd. The offer of USD 179.25 per share resulted in CSL acquiring 94% of Vifor Pharma shares as of March 22, 2022. The definitive result will be published on March 28, 2022, confirming the fulfillment of offer conditions. CSL has waived the 80% acceptance rate requirement, declaring the tender offer successful. Vifor Pharma specializes in treatment solutions for iron deficiency and nephrology.
CSL Behring AG announced the interim results of its public tender offer for Vifor Pharma Ltd. shares at USD 179.25 each. As of March 2, 2022, CSL holds 74% of Vifor's shares and waived the 80% acceptance condition, declaring the offer successful. An additional acceptance period for the tender offer will start on March 9, 2022, and end on March 22, 2022. Following the offer's completion, CSL plans to seek delisting of Vifor shares from the Swiss Exchange. This acquisition aims to enhance CSL's presence in iron deficiency and nephrology sectors.
CSL Behring AG, a subsidiary of CSL Limited (ASX: CSL; USOTC: CSLLY), has announced a strong acceptance for its public tender offer to acquire Vifor Pharma Ltd. The provisional interim result reveals that CSL holds 74% of Vifor's publicly listed shares as of March 2, 2022. CSL intends to waive the 80% acceptance condition if definitive results are similar or better. The next acceptance period is set for March 9-22, 2022, pending successful completion of the offer. The regulatory approval process remains on track for mid-2022 settlement.
The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Kapruvia® (difelikefalin) for treating chronic kidney disease-associated pruritus in hemodialysis patients. This therapy would be the first of its kind in
Vifor Pharma Group achieved a solid financial performance for 2021, with net sales increasing by
FAQ
What is the market cap of GNHAY (GNHAY)?
